	Application No.	Applicant(s)
Notice of Allowability	09/039,789	CARVER ET AL.
	Examiner	Art Unit
	Arlen Soderquist	1743
The MAILING DATE of this communication appear All claims being allowable, PROSECUTION ON THE MERITS IS (herewith (or previously mailed), a Notice of Allowance (PTOL-85) of NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGOT Of the Office or upon petition by the applicant. See 37 CFR 1.313	or son the cover sheet with the coor REMAINS) CLOSED in this appropriate communication is subject	oplication. If not included in will be mailed in due course. <b>THIS</b>
1.   This communication is responsive to the Appeal Brief filed I	March 24, 2004.	
2. X The allowed claim(s) is/are 27-30,32,35,38 and 40-46.		
3. $igotimes$ The drawings filed on <u>16 March 1998</u> are accepted by the E	xaminer.	
4. Acknowledgment is made of a claim for foreign priority und a) All b) Some* c) None of the:  1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)).  * Certified copies not received:  Applicant has THREE MONTHS FROM THE "MAILING DATE" of noted below. Failure to timely comply will result in ABANDONMITHIS THREE-MONTH PERIOD IS NOT EXTENDABLE.  5. A SUBSTITUTE OATH OR DECLARATION must be submit INFORMAL PATENT APPLICATION (PTO-152) which gives (a) including changes required by the Notice of Draftsperson (b) including changes required by the attached Examiner's Paper No./Mail Date  [b] Identifying indicia such as the application number (see 37 CFR 1.3 each sheet. Replacement sheet(s) should be labeled as such in the centre of the priority and the deposent attached Examiner's comment regarding REQUIREMENT Fatalone (see 37 CFR 1.3 each sheet. Replacement sheet(s) should be labeled as such in the deposent attached Examiner's comment regarding REQUIREMENT Fatalone (see 37 CFR 1.3 each sheet. Replacement sheet(s) should be labeled as such in the deposent sheet (see 37 CFR 1.3 each sheet. Replacement sheet(s) should be labeled as such in the deposent sheet. Replacement sheet(s) should be labeled as such in the deposent sheet (see 37 CFR 1.3 each sheet. Replacement sheet(s) should be labeled as such in the deposent sheet (see 37 CFR 1.3 each sheet. Replacement sheet(s) should be labeled as such in the deposent sheet (see 37 CFR 1.3 each sheet. Replacement sheet(s) should be labeled as such in the deposent sheet (see 37 CFR 1.3 each sheet. Replacement sheet(s) should sheet sheet (see 37 CFR 1.3 each sheet. Replacement sheet(s) should sheet sheet (see 37 CFR 1.3 each sheet. Replacement sheet(s) should sheet sheet (see 37 CFR 1.3 each sheet. Replacement sheet(s) should sheet sheet (see 37 CFR 1.3 each sheet (see 37 CFR 1.3 each sheet (see 37 CFR 1.3 each sheet (see 3	been received. been received in Application No uments have been received in this of this communication to file a reply ENT of this application.  tted. Note the attached EXAMINER is reason(s) why the oath or declar be submitted. on's Patent Drawing Review ( PTC Amendment / Comment or in the B4(c)) should be written on the draw he header according to 37 CFR 1.121	s national stage application from the complying with the requirements of complying with the requirement of complying with the
Attachment(s)  1. ☑ Notice of References Cited (PTO-892)  2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)  3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date  4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ☐ Interview Summar Paper No./Mail Da B), 7. ☐ Examiner's Amend	ate

Application/Control Number: 09/039,789

Art Unit: 1743

•

1. The following is an examiner's statement of reasons for allowance: the art of record does not teach or fairly suggest the claimed method and apparatus. The prior rejection on the basis of lack of enablement has been withdrawn for the following reasons. Upon further consideration examiner determined that it would be possible for the claimed invention to be practiced even in a device or method in which there is only one reagent container and a single lysing agent. In claim 27 the selecting step is not required to be performed by the instrument and therefore could be done by the operator based on the input of the species. The only restriction would be when a single reagent container and/or a single lysing agent is used the practice of the claims must allow the advantage found on page 25, line 17 to page 26, line 5 of the instant specification to be obtained. This section of the instant specification is reproduced below with added emphasis.

"Another advantage of the present invention, is that the processing and control unit can automatically optimize sample analysis on a species-by-species basis. The database of the processing and control unit can contain information on the predetermined volumes of the lysing agents for all species encountered in this type of hematology system. Thus, the operator does not need to be concerned with preparing the specific blood/reagent mixture for each type of species being tested. Rather, the operator simply inputs the type of species on the keyboard unit, and the processing and control unit automatically determines the quantities of the lysing agents based on the type of species, and then automatically controls the operation of the pump unit to aspirate the predetermined volumes of lysing agents, and to mix them with the sample/diluent mixture in the mixing cuvette."

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

2. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. The additional art relates to processing of nonhuman blood samples for particle or cell counting in veterinary applications, but does not teach the claimed invention.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Arlen Soderquist whose current telephone number is (571) 272-1265 as a result of the examiner moving to the new USPTO location. The examiner's schedule is variable between the hours of about 5:30 AM to about 5:00 PM on Monday through Thursday and alternate Fridays.

Art Unit: 1743

A general phone number for the organization to which this application is assigned is (571) 272-1700. The fax phone number to file official papers for this application or proceeding is (703) 872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Arlen Sochenguist
June 3, 2004

ARLEN SODERGUIG.
PRIMARY EXAMINER